Amelioration of bromobenzene hepatotoxicity by *Withania somnifera* pretreatment: Role of mitochondrial oxidative stress

Mahima Vedi, Mahaboobkhan Rasool, Evan Prince Sabina*

**VIT University, Vellore 632014 Tamil Nadu, India**

**A B S T R A C T**

The present study investigated the possible protective role of *Withania somnifera* (Linn.) Dunal (Solanaceae) root powder against bromobenzene-induced oxidative damage in rat liver mitochondria. Administration of bromobenzene (10 mmol/kg body weight) to rats resulted in increased levels of liver marker enzymes, lipid peroxidation, TNF-α, IL-1β and VEGF. There was also marked depletion in the levels of mitochondrial enzymes and antioxidant activity. Pre-treatment with *W. somnifera* significantly decreased the levels of liver marker enzymes, TNF-α, IL-1β, VEGF and ameliorated histopathological manifestations in bromobenzene-treated rats. The molecular docking analysis predicted that the pro-inflammatory mediator NF-κB showed significant interaction with selected various active components of *W. somnifera* (withaferin A, withanolide D and withanolide E). This study demonstrates a good protective effect of *W. somnifera* against bromobenzene-induced oxidative stress.

© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/3.0/](http://creativecommons.org/licenses/by-nc-nd/3.0/)).

1. Introduction

Bromobenzene (C₇H₅Br) is a well-known organic solvent and has profound use in the manufacture of various drugs and chemicals. It is metabolized in the liver by primary cytochrome enzymes to form various oxides of bromobenzene, of which bromobenzene-3, 4-oxide is highly reactive. Bromobenzene-3, 4-oxide is sequestered by binding with reduced glutathione (GSH) and subsequently depleting hepatic glutathione levels. This results in reduced protection against intracellular reactive oxygen species (ROS) leading to secondary events such as mitochondrial dysfunction, changes in membrane permeability and oxidative stress [1]. Mitochondria is a vital site for energy metabolism and ATP production. Hence, its malfunction leads to cellular damage and contributes to a wide range of diseases [2]. It can be suggested that mitochondrial dysfunction would be diminished by enriching the mitochondria with antioxidants, thereby reducing the oxidative stress.

Recent studies have focussed on the potential of various natural compounds against liver pathological conditions. Silymarin and N-acetyl-L-cysteine are being already used...
in the clinical treatment of liver injury and they exhibit a potent hepatoprotective activity, but with certain limitations such as gastric irritation, allergies and limited efficacy [3,4]. This indicates that there is still the need of finding highly effective and reliable drugs with minimal side effects for the prevention of acute liver failure.

Withania somnifera (Linn) Dunal (Solanaceae) is a well-known Ayurvedic medicine known to possess pharmacological properties such as anti stress, antioxidant, immunomodulating and anti-arthritic activities [5,6]. These properties may be due to the presence of various biologically active chemical constituents such as alkaloids (isopellertierine, anferine), steroidal lactones (withanolides, withaferins), saponins containing an additional acyl group (sitotinoside VII and VIII), and withanolides with a glucose at carbon 27 (sitotinoside XI and X) [7,8]. The roots of W. somnifera are the most pharmacologically active part of the plant and are known to possess free radical scavenging and antioxidant activity [9]. Therefore, an attempt was made to evaluate the hepatoprotective effect of W. somnifera root powder against bromobenzene-induced acute liver necrosis which has not been reported to the best of our knowledge. Silymarin has been used as the standard reference drug in the present study. Also, the effect of selected active components of W. somnifera on NF-κB was analyzed using molecular docking.

2. Materials and methods

2.1. Animals

Wistar albino rats of either sex, weighing 120–150 g were obtained from animal house, VIT University, Vellore. They were fed with commercial pelleted feed from Hindustan Lever Ltd. (Mumbai, India) and water ad libitum. The animals were maintained according to the guidelines recommended by the Committee for the Purpose of Supervision and Control of Experiments on Animals (CPSCEA), Government of India, Chennai, Tamil Nadu. Experimental procedure for the present study has been approved by the ethical committee (VIT/IAEC/VIII/17) of VIT University, Vellore, India.

2.2. Drugs and chemicals

Commercially available W. somnifera root powder was obtained from Indian Medical Practitioners Co-operative Stores and Society (IMCOPS, Chennai, India). Silymarin, a standard hepatoprotective drug, was obtained from Micro Labs Ltd (Goa, India). All other reagents used were standard laboratory reagents of analytical grade and were purchased locally. The effective dosage of bromobenzene [10] and W. somnifera [11] were based on the basis of previous studies. Aqueous suspension of silymarin (100 mg/kg body weight) and W. somnifera (250 and 500 mg/kg body weight) were made in double distilled water for administration to rats.

3. Experimental procedure

Animals were allocated randomly in six groups of six animals each. In this study, all group of rats except group I and group VI received bromobenzene dosage (intragastric tube) only once. The animals were treated as shown in Table 1:

All six groups were fasted for 24 h before and 19 h after the administration of silymarin/W. somnifera/bromobenzene/coconut oil. After the collection of blood, samples from liver tissues (approximately 0.05–0.1 g) were homogenized in phosphate buffer (pH 7.4) to give 20% w/v homogenate [12]. This homogenate was centrifuged at 3000 g and 4°C for 10 min; the supernatant was stored at −20°C until analysis.

3.1. Serum biochemical parameters, antioxidant status, plasma ceruloplasmin and total sulfhydril group determination

The activities of aspartate aminotransferase (AST), alkaline aminotransferase (ALT), alkaline phosphatase (ALP), albumin, total bilirubin and direct bilirubin were determined according to the manufacturer’s protocol using kits (Autospan diagnostics, Bangalore, India) in the serum of control and experimental rats. Antioxidant status was determined in the plasma and liver tissue of control as well as experimental rats. Lipid peroxidation was determined by the procedure of Ohkawa et al. [13] and malondialdehyde (MDA), which forms as end product of lipid peroxidation, was measured. Superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-s-transferase (GST) and reduced glutathione were also evaluated [14–18]. Total protein was estimated according to the method of Lowry et al. [19] using bovine serum albumin as standard. Furthermore, plasma ceruloplasmin [20] and total sulfhydril groups [21] were measured in plasma and liver respectively in the control and experimental rats.

3.2. Isolation of mitochondria

For the isolation of liver mitochondria, the method of Johnson and Lardy [22] was followed and the protein

| Table 1 | Experimental animal design for the study. |
|---------|------------------------------------------|
| Groups  | Treatment |
| Group I | Normal control (received single dose of 0.1 ml coconut oil through intragastric intubation once and sacrificed after 19 h) |
| Group II | Bromobenzene (10 mmol in 0.1 ml coconut oil by intragastric intubation) once and sacrificed after 19 h |
| Group III | Withania somnifera (250 mg/kg, orally) for 8 days and a single dose of bromobenzene (10 mmol/kg in 0.1 ml coconut oil, intragastric intubation) on the 8th day and sacrificed after 19 h |
| Group IV | Withania somnifera (500 mg/kg, orally) for 8 days and a single dose of bromobenzene (10 mmol/kg in 0.1 ml coconut oil, intragastric intubation) on the 8th day and sacrificed after 19 h |
| Group V | Silymarin (100 mg/kg, orally) for 8 days and a single dose of bromobenzene (10 mmol/kg in 0.1 ml coconut oil intragastric intubation) on the 8th day and sacrificed after 19 h |
| Group VI | Withania somnifera (500 mg/kg, orally) for 8 days and sacrificed after 19 h |
content was measured according to manufacturer’s protocol using kit obtained from Autospan diagnostics, Bangalore, India.

3.3. Evaluation of mitochondrial enzymes
Isocitrate dehydrogenase activity was measured using a calibration curve with α-ketoglutarate as standard and was expressed as nmol of α-ketoglutarate formed/ h/mg protein [23]. The activity of α-ketoglutarate dehydrogenase was assayed by the method of Reed and Mukherjee [24] and the reaction was terminated by the addition of tricarboxylic acid (TCA). The colour developed was measured at 540 nm. A standard containing potassium ferrocyanide was assayed simultaneously. The activity of succinate dehydrogenase was assayed according to the method of Slater and Bonner [25] using sodium succinate and potassium ferricyanide, and the change in optical density (OD) was recorded at 15 s intervals for 5 min at 420 nm. Succinate dehydrogenase activity was expressed as nmol of succinate oxidized/min/mg protein. The activity of malate dehydrogenase was assayed by the method of Mehler et al. [26]. Reaction mixture containing phosphate buffer, NADH, oxaloacetate and mitochondrial suspension was prepared. The change in OD at 340 nm was measured for 2 min at intervals of 15 s in a UV spectrophotometer. The activity of the enzyme was expressed as nmol of NADH oxidized/min/mg protein. The activity of cytochrome c oxidase was assayed according to the method of Pearl et al. [27] and the change in absorbance was recorded at 550 nm for 5 min at intervals of 15 s. The enzyme activity was expressed as change in absorbance/min/mg protein. The enzyme activity of NADH dehydrogenase was assayed by the method of Minakami et al. [28] and was expressed as nmol of NADH oxidized/min/mg protein.

3.4. Measurement of serum TNF-α, IL1β and VEGF
The serum concentrations of TNF-α, IL1β and VEGF were measured by ELISA according to manufacturer’s protocol using commercial kits (Krishgen BioSystems, Bangalore, India) and were expressed in nanograms per millilitre.

3.5. Docking study of active components of W. somnifera with NF-κB
A three dimensional structure of the binding domain of NF-κB (PDB ID: 3U21) was downloaded using the protein databank database (http://www.rcsb.org/pdb/home.do) (Fig. 4). The sequences of selected active components of W. somnifera such as withaferin A, withanolide D and withanolide E were obtained from pubchem (http://www.ncbi.nlm.nih.gov.pccompound) and submitted in SMILES format on Corina (http://www.molecular-networks.com/node/84) to generate 3-Dimensional structures of the ligands (Fig. 4). Docking was done using PatchDock server and the scoring in PatchDock is based on both geometric fit and atomic desolvation energies.

3.6. Histopathological studies
Immediately after sacrifice, a portion of the liver was fixed in 10% formalin, then washed, dehydrated in descending grades of isopropanol and finally rinsed with xylene. The tissues were then embedded in molten paraffin wax. Sections were cut at 5 mm thickness, stained with haematoxylin and eosin and were observed microscopically for histopathological changes (400× magnification).

3.7. Statistical analysis
All results were expressed as mean ± SD compared to normal control rats. The intergroup variation between various groups was measured by one way analysis of variance (ANOVA) and the comparisons between the groups were conducted by Student Newman–Keuls’s test using the software Graph Pad InStat version 3.10. Results were considered statistically significant when *p < 0.05. Comparisons were made as follows: a-group I vs groups II–VI; b-group II vs group III–VI.

4. Results
4.1. Effects of W. somnifera on liver weight and serum biochemical parameters
The results observed in groups which were pre-treated with W. somnifera and silymarin with respect to the induction of hepatotoxicity using bromobenzene are given in Table 2 and 3. Rats which were treated with bromobenzene developed liver damage as evidenced by increase in the activities of liver functional markers; ALT, AST, ALP, total and direct bilirubin (Table 3). Moreover, there was an increase in the liver weight and decrease in the albumin levels in bromobenzene treated group as compared to the control group of rats (Table 2). W. somnifera (250

### Table 2

| Groups                               | Liver weight (g) | Body weight initial (g) | Body weight before sacrifice (g) |
|--------------------------------------|------------------|-------------------------|----------------------------------|
| Group I (Control)                    | 5.19 ± 0.55      | 118.32 ± 13.20          | 122.17 ± 14.30                   |
| Group II (Bromobenzene-10 mmol/kg)  | 6.27 ± 0.27a     | 117.17 ± 15.31          | 120.50 ± 12.07                   |
| Group III (W. somnifera -250 mg/kg + Bromobenzene-10 mmol/kg) | 5.38 ± 0.18b | 119.05 ± 8.15          | 125.16 ± 11.09                   |
| Group IV (W. somnifera -500 mg/kg + Bromobenzene-10 mmol/kg) | 5.16 ± 0.13b | 118.00 ± 15.33          | 129.50 ± 13.41                   |
| Group V (Silymarin-100 mg/kg + Bromobenzene-10 mmol/kg) | 4.86 ± 0.26b | 116.33 ± 14.70          | 119.36 ± 12.80                   |
| Group VI (W. somnifera -500 mg/kg)  | 5.47 ± 0.36b     | 120.75 ± 10.90          | 129.87 ± 14.97                   |

Each value represents the mean ± SD of six rats. Comparisons were made as follows: a-group I vs groups II, III, IV, V, VI; b— group II vs group III, IV, V, VI. Statistical analysis was calculated by one way analysis of variance (ANOVA) followed by the Student Newman–Keuls’s test.

* The symbols represent statistical significance at p < 0.05.
Table 3
Effect of the administration of bromobenzene (BB) on levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin, direct and total bilirubin with or without prior administration of *Withania somnifera* (WS) in serum of control and experimental rats.

| Parameters                  | Group I (Control) | Group II (BB – 10 mmol/kg) | Group III (WS – 250 mg/kg + BB) | Group IV (WS – 500 mg/kg + BB) | Group V (Silmarin – 100 mg/kg + BB) | Group VI (WS – 500 mg/kg) |
|-----------------------------|-------------------|----------------------------|----------------------------------|---------------------------------|----------------------------------|--------------------------|
| AST (U/L)                   | 114.04 ± 0.73     | 236.07 ± 1.15a             | 145.1 ± 0.52a b                  | 134.45 ± 3.58a b                | 136.26 ± 3.01a b               | 128.14 ± 1.63b          |
| ALT (U/L)                   | 48.44 ± 3.12      | 113.09 ± 1.65a             | 57.13 ± 1.67b                    | 55.25 ± 2.51 a b                | 57.68 ± 2.32 b                 | 54.41 ± 1.77 b          |
| ALP (U/L)                   | 87.04 ± 3.08      | 167.88 ± 9.95 a            | 113.04 ± 3.16 a b                | 106.02 ± 6.70 a b               | 135.01 ± 2.91 a               | 103.60 ± 7.61 b         |
| Total Bilirubin (mg/dl)     | 0.88 ± 0.07       | 3.29 ± 0.48a               | 2.40 ± 0.23a b                   | 1.28 ± 0.08b                    | 1.51 ± 0.09a b                 | 1.01 ± 0.03b            |
| Direct Bilirubin (mg/dl)    | 0.03 ± 0.01       | 0.36 ± 0.05 a              | 0.19 ± 0.01 a b                  | 0.12 ± 0.01 a b                 | 0.15 ± 0.02 a b               | 0.04 ± 0.01 b           |
| Albumin (g/l)               | 42.52 ± 1.44      | 35.38 ± 1.62a              | 41.36 ± 1.38                     | 44.80 ± 1.60b                   | 48.15 ± 0.54b                  | 42.18 ± 0.21b           |

Each value represents the mean ± SD of six rats. Comparisons were made as follows: a-group I vs groups II, III, IV, VI; b-group II vs group III, IV, V, VI. Statistical analysis was calculated by one way analysis of variance (ANOVA) followed by the Student Newman–Keul's test.

The symbols represent statistical significance at p < 0.05.

and 500 mg/kg) pre-treatment restored the levels of ALT, AST, ALP, total bilirubin, direct bilirubin and albumin in bromobenzene treated group of rats.

4.2. Effect of *W. somnifera* on antioxidant levels

Malondialdehyde (MDA) is the main oxidative degradation product during lipid peroxidation and functions as a marker of oxidative injury to cellular membranes. Antioxidant status was found to be depleted (Table 4) accompanied with an increase in the levels of MDA in both plasma and hepatic tissue of bromobenzene-treated group as compared to the control group. Levels of CAT, SOD and glutathione were significantly enhanced, whereas levels of MDA were reduced in *W. somnifera* and silmarin treated groups. The highest dose (500 mg/kg) of *W. somnifera*

Table 4
Effect of the administration of bromobenzene (BB) on antioxidant status, lipid peroxidation, plasma ceruloplasmin and total sulphhydryl groups with or without prior administration of *Withania somnifera* (WS) in plasma and liver tissue homogenate of control and experimental rats.

| Parameters                  | Group I (Control) | Group II (BB – 10 mmol/kg) | Group III (WS – 250 mg/kg + BB) | Group IV (WS – 500 mg/kg + BB) | Group V (Silmarin – 100 mg/kg + BB) | Group VI (WS – 500 mg/kg) |
|-----------------------------|-------------------|----------------------------|----------------------------------|---------------------------------|----------------------------------|--------------------------|
| Liver Catalase (Units/min/mg protein) | 64.05 ± 0.93     | 21.57 ± 0.30a              | 31.94 ± 1.52b                    | 60.18 ± 7.09b                   | 59.4 ± 8.47a b                 | 61.84 ± 2.08b          |
| SOD (U/mg protein)          | 68.85 ± 7.06      | 23.85 ± 2.07a              | 43.90 ± 4.82a b                  | 66.9 ± 7.84b                    | 63.5 ± 7.12b                   | 66.42 ± 7.83b          |
| Lipid Peroxidation (nmol/mg protein) | 1.44 ± 0.03     | 3.25 ± 0.09a               | 1.33 ± 0.03b                     | 1.50 ± 0.06b                    | 1.51 ± 0.04b                   | 1.56 ± 0.02b           |
| GST (nmol/minmg protein)    | 19.97 ± 0.10      | 7.65 ± 0.14a               | 15.94 ± 0.15a b                  | 19.43 ± 0.31b                   | 19.12 ± 0.16b                  | 19.57 ± 0.17b          |
| Reduced Glutathione (nmol/mg protein) | 7.95 ± 0.21     | 3.33 ± 0.67a               | 8.27 ± 0.12b                     | 7.93 ± 0.47                     | 8.25 ± 0.49                    | 7.68 ± 0.12            |
| Glutathione Peroxidase (µg of GSH utilized/min/mg protein) | 26.42 ± 3.85     | 16.5 ± 1.93a              | 24.40 ± 3.02b                    | 25.70 ± 2.20b                   | 25.08 ± 1.16b                  | 25.76 ± 4.03b          |
| Total Sulphhydryl groups (nmol/mg protein) | 18.5 ± 3.08     | 7.08 ± 0.79a              | 12.23 ± 1.52a b                  | 15.16 ± 1.60b                   | 13.50 ± 2.88a b               | 17.83 ± 2.31           |
| Plasma Catalase (Units/min/mg protein) | 62.99 ± 6.85     | 43.55 ± 1.45a              | 55.32 ± 3.59                     | 59.68 ± 1.75b                   | 56.13 ± 2.83                    | 60.8 ± 3.02a          |
| SOD (U/mg protein)          | 52.60 ± 7.77      | 24.50 ± 2.73a              | 42.4 ± 4.49b                     | 50.21 ± 4.12a b                 | 42.35 ± 10.46b                  | 51.28 ± 5.47           |
| Lipid Peroxidation (nmol/mg protein) | 3.04 ± 0.12     | 6.18 ± 0.82a               | 4.16 ± 0.17a b                   | 3.60 ± 0.31b                    | 3.72 ± 0.71b                    | 3.83 ± 0.26            |
| GST (nmol/minmg protein)    | 16.63 ± 2.36      | 8.41 ± 2.92a               | 14.78 ± 0.17                     | 15.27 ± 0.18a                   | 15.22 ± 0.11b                   | 16.32 ± 0.14b          |
| Reduced Glutathione (nmol/mg protein) | 15.86 ± 0.38   | 7.65 ± 0.67a               | 12.89 ± 1.94a                    | 13.26 ± 2.01                    | 10.43 ± 1.45a                   | 14.69 ± 0.27a          |
| Glutathione Peroxidase (µg of GSH utilized/min/mg protein) | 29.16 ± 3.17     | 18.58 ± 2.92a              | 27.12 ± 2.24                     | 23.42 ± 1.94b                   | 28.94 ± 2.11                    | 28.32 ± 1.23           |
| Plasma ceruloplasmin (g/l)  | 0.75 ± 0.08       | 1.89 ± 0.62a               | 0.94 ± 0.07                      | 0.77 ± 0.12                     | 0.89 ± 0.10                     | 0.78 ± 0.44            |

Each value represents the mean ± SD of six rats. Comparisons were made as follows: a-group I vs groups II, III, IV, VI; b-group II vs group III, IV, V, VI. Statistical analysis was calculated by one way analysis of variance (ANOVA) followed by the Student Newman–Keul’s test.

The symbols represent statistical significance at p < 0.05.
Table 5
Effect of the administration of bromobenzene with or without the prior administration of Withania somnifera or silymarin on mitochondrial enzymes in liver of control and experimental rats.

| Parameters                        | Group I (Control) | Group II (BB – 10 nmol/kg) | Group III (WS – 250 mg/kg + BB) | Group IV (WS – 500 mg/kg + BB) | Group V (Silymarin – 100 mg/kg + BB) | Group VI (WS – 500 mg/kg) |
|-----------------------------------|-------------------|-----------------------------|--------------------------------|--------------------------------|----------------------------------|---------------------------|
| Isocitrate dehydrogenase (U/mg protein) | 404.11 ± 9.60     | 293.14 ± 11.01 a b          | 348.13 ± 10.78 a b            | 391.93 ± 10.34 a b            | 374.62 ± 10.17 a b            | 397.07 ± 11.82 b          |
| α-Ketoglutarate dehydrogenase (U/mg protein) | 99.93 ± 8.71     | 59.12 ± 6.92 a c           | 89.53 ± 4.31 a c            | 94.10 ± 10.52 a c            | 85.08 ± 10.13 a c            | 98.94 ± 1.95 b           |
| Succinate dehydrogenase (U/mg protein) | 46.12 ± 2.52     | 18.21 ± 1.78 a c           | 34.12 ± 2.53 a c            | 39.94 ± 2.56 a b            | 31.45 ± 1.93 a c            | 45.11 ± 1.46 b           |
| Malate dehydrogenase (U/mg protein) | 283.52 ± 16.53   | 174.22 ± 19.24 a c         | 220.83 ± 18.53 a c          | 263.12 ± 10.41 a c          | 253.14 ± 7.28 a c           | 278.14 ± 9.53 b          |
| NADH dehydrogenase (U/mg protein) | 46.24 ± 4.62     | 19.93 ± 3.46 a c           | 31.56 ± 2.93 a c            | 38.43 ± 3.48 a c            | 31.57 ± 8.34 a c            | 42.14 ± 3.23 b           |
| Cytochrome-c- oxidase (U/mg protein) | 12.43 ± 1.47     | 3.53 ± 1.45 a c           | 5.31 ± 1.97 a c            | 9.25 ± 1.32 a c            | 8.57 ± 1.20 a c             | 11.92 ± 2.04 b           |

Each value represents the mean ± SD of six rats. Comparisons were made as follows: a – group I vs groups II, III, IV, V, VI; b – group II vs group III, IV, V, VI; a, b, c, d – group IV vs group I, II, III, IV; a, b, c, d – group IV vs group I, II, III, IV. The symbols represent statistical significance at p < 0.05. Statistical analysis was calculated by one-way analysis of variance (ANOVA) followed by the Student Newman–Keul’s test.

Results showed maximum recovery of antioxidant activities in the experimental animals.

4.3. Effects of W. somnifera on total sulphydryl groups and plasma ceruloplasmin content

Table 4 shows increased plasma ceruloplasmin levels while there was depletion in the total sulphydryl levels in bromobenzene treated group in comparison to the control group of rats. Pre-administration of W. somnifera restored the levels of plasma ceruloplasmin and total sulphydryl groups to near normal levels.

4.4. Effect of W. somnifera on mitochondrial enzymes

The activities of TCA cycle enzymes (Isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, succinate dehydrogenase, malate dehydrogenase) and respiratory enzymes (NADH dehydrogenase and cytochrome c oxidase) were found to be significantly reduced (p < 0.05).
due to the administration of bromobenzene to rats. *W. somnifera* (250 and 500 mg/kg) or silymarin pre-treatment restored the activities of mitochondrial enzymes and brought them to near normal levels (Table 5).

### 4.5 Measurement of serum TNF-α, IL1β and VEGF

It is already known that pro-inflammatory cytokines (TNF-α and IL1β) and signal protein (VEGF) promote oxidative stress, therefore, their concentration in serum was found to be significantly enhanced in the bromobenzene alone treated group (Figs. 1–3). Prior administration of *W. somnifera* (250 and 500 mg/kg) and silymarin prevented the increase in serum concentrations of TNF-α, IL1β and VEGF.

### 4.6 Docking analysis

The molecular docking analyses showed that there was a strong interaction between selected active components of *W. somnifera* i.e., Withanolide D, Withanolide E and Withdrawin A with NF-κB. Due to these interactions, the selected active components of *W. somnifera* block normal pathway of NF-κB for release of inflammatory mediators (Fig. 4 and Table 6).

### 4.7 Histopathological examination of liver damage

The light microscopy examination of the representative sections of control rat liver clearly shows complete hepatic lobules with distinct hepatic cells. Hepatic cells were arranged in cord like fashion, which were separated by sinusoids and central vein was clearly visible (Fig. 5a) and the liver sections of bromobenzene treated rats showed massive fatty changes (Fig. 5b). Pre-treatment with *W. somnifera* (250 and 500 mg/kg) was effective in restoring the bromobenzene-induced histopathological lesions, however highest dose was found to be more effective (Fig. 5c and d). The histological architecture of liver

---

**Fig. 2.** Effect of the administration of bromobenzene on serum levels of IL1β with or without prior administration of *Withania somnifera* in control and experimental rats. Each value represents the mean ± SD of six rats. Comparisons were made as follows: a-group I vs groups II, III, IV, V, VI; b– group II vs group III, IV, V, VI. The symbols represent statistical significance at *p* < 0.05. Statistical analysis was calculated by one-way ANOVA followed by the Student Newman–Keul’s test.

**Fig. 3.** Effect of the administration of bromobenzene on serum levels of VEGF with or without prior administration of *Withania somnifera* in control and experimental rats. Each value represents the mean ± SD of six rats. Comparisons were made as follows: a-group I vs groups II, III, IV, V, VI; b– group II vs group III, IV, V, VI. The symbols represent statistical significance at *p* < 0.05. Statistical analysis was calculated by one-way ANOVA followed by the Student Newman–Keul’s test.
sections of rats that received silymarin showed absence of cell necrosis, but with minimal inflammatory conditions (Fig. 5e). In case of administration of *W. somnifera* at 500 mg/kg dose, the micrographs exhibited an almost normal architecture (Fig. 1f).

### Table 6

Docking studies of active components of *Withania somnifera* (Withaferin A, Withanolide D and Withanolide E) with pro-inflammatory mediator NF-kB.

| Active component | Atomic contact energy (ACE) | Docking score | No. of hydrogen (H) bonds | Residues involved | Length of the H bond |
|------------------|-----------------------------|---------------|---------------------------|------------------|----------------------|
| Withaferin A     | $-234.51$                   | 5120          | 1                         | Leu-H62          | 1.3 Å               |
| Withanolide D    | $-232.17$                   | 5520          | 1                         | Ile-H63          | 2.7 Å               |
| Withanolide E    | $-205.70$                   | 5378          | 1                         | Asn-O33          | 3.0 Å               |

### 5. Discussion

Bromobenzene is subjected to biotransformation in the liver by cytochrome P450 enzymes to form highly hepatotoxic metabolites [29]. It is known to cause functional and
morphological alterations in the liver cell membrane, as evidenced by increase in AST, ALT and ALP, which were in accordance with the previous studies [30]. Pre-treatment with *W. somnifera* depicted its protective action against cellular injury and normalized the levels of AST, ALT and ALP, which may be due to its membrane stabilizing action (Table 3). A high concentration of bilirubin in serum is an indication for increased erythrocyte degeneration rate. *W. somnifera* helped in decreasing the significantly (p < 0.05) altered levels of total and direct bilirubin, thus bringing liver to normal functionality (Table 3).

It is known that BB-3,4 oxide causes glutathione depletion, therefore, a decrease of the general cellular red/ox balance will automatically increase the ROS level (there are other sources to ROS than a damaged mitochondrion). Furthermore, BB metabolites such as bromobenzene phenols can be oxidized to hydroquinones, which also may form ROS. Intragastric intubation of bromobenzene at 10 mmol/kg in 19 h elicited a significant alteration of some antioxidant mechanisms and drug metabolizing enzymes in the liver [2,31]. Pre-treatment with *W. somnifera* at both doses caused marked elevation in the levels of these

---

**Fig. 5.** Histopathological monograph of the liver. (a) Group I (Control), (b) Group II (bromobenzene), (c) Group III (*Withania somnifera* – 250 mg/kg + bromobenzene), (d) Group IV (*Withania somnifera* – 500 mg/kg + bromobenzene), (e) Group V (Silymarin 100 mg/kg + bromobenzene), and (e) Group VI (*Withania somnifera* – 500 mg/kg), all the pictures are taken under 400× magnification.
antioxidants which may be associated with its free radical scavenging and antioxidant enhancing abilities as reported in previous studies. Furthermore, reduction in total sulphydryl groups possibly means that these might have been used to combat the action of toxic by-products formed from bromobenzene metabolism [32]. Plasma ceruloplasmin levels were also increased due to acute phase response [33] in bromobenzene treated rats. The active components of Withania somnifera probably react directly with and detoxify the reactive electrophilic bromobenzene (BB) metabolite BB-3,4-oxide, as well as possible ROS molecules formed. Furthermore, the ROS molecules can be secondary to damage mitochondrion as suggested, but the mitochondrial damage may not be the only source for ROS. Also, there was a decrease in the activities of liver mitochondrial enzymes due to the administration of bromobenzene to rats and Withania somnifera pre-treatment prevented the decrease in their levels, which is in concordance with the previous studies [34].

Reactive oxygen species promote inflammation by enhancing the activation of transcription factor NF-κB, which controls the formation of cytokines, chemokines, and adhesion molecules [35,36]. In the present study, through docking analysis it was shown that some selected active components of Withania somnifera show significant interactions with NF-κB. Also, in rats which were treated with bromobenzene only, levels of TNF-α, IL1β and VEGF were found to be elevated as a result of inflammation (Figs. 1–3). Prior administration of Withania somnifera was able to reduce their levels in serum in a dose dependent manner. Thus, it can be suggested that Withania somnifera is able to counteract bromobenzene-induced hepatotoxicity and oxidative stress due to the presence of its active components by interacting with the inflammatory mediator, NF-κB (Fig. 4).

The hepatoprotective effect was supported by the liver histological changes produced by Withania somnifera as compared to the control and bromobenzene treated rats. Withania somnifera pre-treatment markedly attenuated the bromobenzene-induced liver cell necrosis in a dose dependent manner and restored more or less the same histopathological picture as observed in the control group (Fig. 5c and d).

6. Conclusion

It can be concluded from this study that the roots of Withania somnifera offer significant dose-dependent protection against bromobenzene-induced liver injury to rats and the hepatoprotective effect was comparable to silymarin, which is the standard drug of reference for hepatoprotection. Moreover, results obtained in this study support the antioxidant properties of Withania somnifera [34]. However, further pharmacological evidence supporting the role of Withania somnifera against bromobenzene-induced liver injury is needed and more studies are required to explore the mechanisms for the same.

Conflict of interests

The authors declare that there is no conflict of interest between them.

Transparency document

The Transparency document associated with this article can be found in the online version.

Acknowledgements

The authors are thankful to VIT University for the infrastructure and support provided for the research.

References

[1] W.H.M. Hejine, R.H. Stireum, M. Sliper, P.J. Bladeren, B. Oommen, Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomic approach, Biochem. Pharmacol. 2003 (65) (2003) 857–875.
[2] S. Gopi, O.H. Setty, Beneficial effect of the administration of Hemidesmus indicus against bromobenzene induced oxidative stress in rat liver mitochondria, J. Ethnopharmacol. 127 (2010) 200–220.
[3] M.W. Fried, V.J. Navarro, N. Afshal, et al., Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C successfully treated with interferon therapy: a randomized controlled trial, J. Am. Med. Assoc. 308 (2012) 274–282.
[4] R.H. Squires, A. Dhawan, E. Alonso, et al., Pediatric Acute Liver Failure Study Group. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo-controlled clinical trial, Hepatology 57 (4) (2012) 1542–1549.
[5] A. Bhattacharya, M. Ramanathan, S. Ghosal, S.K. Bhattacharya, Effect of Withania somnifera glycowithanolides on iron-induced hepatotoxicity in rats, Phytother. Res. 14 (7) (2010) 568–570.
[6] A. Bhattacharya, S. Ghosal, S.K. Bhattacharya, Antioxidant effect of Withania somnifera glycowithanolides in chronic footshock stress induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum, J. Ethnopharmacol. 74 (2001) 1–6.
[7] M. Rasool, P. Varalakshmi, Suppressive effect of Withania somnifera root powder on experimental gouty arthritis: an in vivo and in vitro study, Chem. Biol. Interact. 164 (3) (2006) 174–180.
[8] G. Singh, P.K. Sharma, R. Dudhe, S. Singh, Biological activities of Withania somnifera, Ann. Biol. Res. 1 (3) (2010) 56–63.
[9] M. Shahrir, M.I. Hossain, F.A. Sharmin, S. Akhter, M.A. Haque, M.A. Bhuiyan, In vitro antioxidant and free radical scavenging activity of Withania somnifera root, IOSR J. Pharm. 3 (2) (2013) 38–47.
[10] S. Gopi, O.H. Setty, Protective effect of Phyllanthus fraternus against bromobenzene induced mitochondrial dysfunction in rat liver mitochondria, Food Chem. Toxicol. 48 (2010) 2170–2175.
[11] E.P. Sabina, M.K. Rasool, M. Vedi, et al., Hepatoprotective and antioxidant potential of Withania somnifera against paracetamol-induced liver damage in rats, Int. J. Pharm. Pharm. Sci. 5 (2) (2013) 648–651.
[12] C.C. Lin, Y.F. Hsu, T.C. Lin, F.L. Hsu, H.Y. Hsu, Antioxidant and hepatoprotective activity of punicalagin and punicalin on carbon tetrachloride induced liver damage in rats, J. Pharmacol. 50 (1998) 789–794.
[13] H. Okawara, N. Ohish, K. Yagi, Assay for lipid peroxides in animal tissues by thiobarbituric acid, Anal. Biochem. 95 (1979) 351–358.
[14] S.L. Marklund, G. Marklund, Involvement of superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase, Eur. J. Biochem. 47 (1974) 469–474.
[15] A.K. Sinha, Colorimetric assay of catalase, Anal. Biochem. 147 (1974) 389–394.
[16] J.T. Rettruk, A.L. Pope, H.E. Ganther, A.B. Swanson, D.G. Hafeman, W.G. Hoekstra, Selenium, biochemical role as a component of glutathione peroxidase purification and assay, Science 17 (1973) 588–590.
[17] W.H. Habig, M.J. Pabst, W.B. Jakoby, Glutathione-S-transferases. The first enzymatic step in mercapturic acid formation, J. Biol. Chem. 249 (1974) 7130–7139.
[18] M.S. Moron, J.W. Depierre, B. Mannervik, Levels of glutathione/glutathione reductase and glutathione-S-transferase activities in rat lung and liver, Biochim. Biophys. Acta 582 (1979) 67–78.
[19] O.H. Lowry, N.J. Rosebrough, A.L. Farr, P.R.J. Randall, Protein measurement with the folin phenol reagent, J. Biol. Chem. 193 (1951) 265–275.
[20] W.F. Sunderman, S. Nomoto, Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity, Clin. Chem. 16 (11) (1970) 903–910.
638

M. Vedi et al. / Toxicology Reports 1 (2014) 629–638

[21] R. Kaushal, K.R. Dave, S.S. Katyare, Paracetamol hepatotoxicity and microsomal function, Environ. Toxicol. Pharmacol. 7 (1999) 67–74.
[22] D. Johnson, H. Lardy, Isolation of liver or kidney mitochondria, in: Methods in Enzymology, Academic Press, London, 1981, pp. 94–96.
[23] J.L. Bell, D.N. Baron, A colorimetric method for determination of isocitrate dehydrogenase, Clin. Chim. Acta 5 (2001) 740–747.
[24] L.J. Reed, R.B. Mukherjee, α-Ketoglutarate dehydrogenase complex from Escherichia coli, in: S.P. Colowick, N.O. Kaplan (Eds.), Methods in Enzymology, vol. 13, Academic Press, New York, 1969, pp. 53–61.
[25] E.C. Slater, W.D.J. Bonner, The effect of fluoride on succinic oxidase system, Biochemistry 52 (1952) 185–195.
[26] A.H. Mehler, A. Kornberg, S. Grisolia, S. Ochoa, The enzymatic mechanism of oxidation-reductions between malate or isocitrate and pyruvate, J. Biol. Chem. 174 (1948) 961–977.
[27] W. Pearl, J. Cascarano, B.W. Zweifach, Microdetermination of cytochrome oxidase in rat tissues by the oxidation of N-phenyl-p-phenylene diamine or ascobic acid, J. Histochem. Cytochem. 2 (1963) 102–104.
[28] S. Minakami, R.L. Ringler, T.P. Singer, Studies on the respiratory chain-linked dihydrodiposphopyridine nucleotide dehydrogenase. I. Assay of the enzyme in particulate and in soluble preparation, J. Biol. Chem. 237 (1962) 569–576.
[29] F. Salvatore, L. Sacchetti, G. Castaldo, Multivariate discriminant analysis of biochemical parameters for the differentiation of clinically confounding liver diseases, Clin. Chim. Acta 257 (1997) 41–58.
[30] M.A. Hamed, N.S. El-Rigal, S.A. Ali, Effects of black seed oil on resolution of hepato-renal toxicity induced by bromobenzene in rats, Eur. Rev. Med. Pharmacol. Sci. 17 (2013) 569–581.
[31] C.Y. Wang, F.L. Ma, J.T. Liu, J.W. Tian, F.H. Fu, Protective effect of sal-vianic acid α on acute liver injury induced by carbon tetrachloride in rats, Biol. Pharm. Bull. 30 (2007) 44–47.
[32] A. Srivastava, T. Shivanandappa, Hepatoprotective effect of the root extract of Decalepis hamiltonii against carbon tetrachloride-induced oxidative stress in rats, Food Chem. 118 (2010) 411–417.
[33] C. Chiarala, I. Giovannini, J.H. Siegel, Patterns of correlation of plasma ceruloplasmin in sepsis, J. Surg. Res. 144 (1) (2008) 107–110.
[34] M. Vedi, M.K. Rasool, E.P. Sabina, Protective effect of administration of Withania somnifera against bromobenzene induced nephrotoxicity and mitochondrial oxidative stress in rats, Ren. Fail. 36 (8) (2014) 1095–1103.
[35] H. Jaeschke, Reactive oxygen and mechanisms of inflammatory liver injury, J. Gastroenterol. Hepatol. 15 (2000) 718–724.
[36] H. Jaeschke, A.J. Cederbaum, J.A. Hinson, D. Pessary, J.J. Lemasters, Mechanisms of hepatotoxicity, Toxicol. Sci. 65 (2002) 166–176.